Skip to main content
Humanwell Healthcare (Group) Co.,Ltd. logo

Humanwell Healthcare (Group) Co.,Ltd. — Investor Relations & Filings

Ticker · 600079 ISIN · CNE000000QW6 LEI · 300300CT1GETYDVFFG34 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,994 across all filing types
Latest filing 2026-05-27 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600079

About Humanwell Healthcare (Group) Co.,Ltd.

https://www.humanwell.com.cn/

Humanwell Healthcare (Group) Co., Ltd. is a global pharmaceutical enterprise focused on the research, development, manufacturing, and distribution of healthcare products. The company specializes in central nervous system medications, particularly anesthetics and analgesics, where it maintains a significant market position. Its diverse portfolio also includes fertility regulation drugs, psychotropic medications, and high-end formulations. Humanwell operates a vertically integrated business model, encompassing active pharmaceutical ingredient production and finished dosage form manufacturing. With a strong emphasis on innovation, the group maintains multiple R&D centers and manufacturing facilities that comply with international quality standards, including US FDA and EU GMP. The company serves global markets through a robust supply chain and strategic partnerships, aiming to provide accessible and high-quality medical solutions across various therapeutic areas.

Recent filings

Filing Released Lang Actions
2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is titled “2025年年度股东会会议资料” and contains detailed meeting materials for the 2025 Annual General Meeting (agenda, meeting rules, board reports, financial statements attachments, voting procedures, etc.). It is clearly the presentation and background materials prepared for the company’s AGM, not the proxy statement or the standalone report itself. Under our taxonomy, this falls under AGM Information (Code: AGM-R).
2026-05-27 Chinese
关于盐酸R-氯胺酮注射液获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 88% confidence The document is a corporate announcement (“公告”) by a Chinese listed company informing investors that its subsidiary has received regulatory approval for a clinical trial notification from the National Medical Products Administration. It is not a financial report, earnings release, dividend notice, or management change. It is a general regulatory update and does not fit any other specific category, so it defaults to Regulatory Filings (RNS).
2026-05-13 Chinese
关于注射用醋酸西曲瑞克获得美国FDA批准文号的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a drug (Cetrorelix Acetate for Injection) by the US FDA. It details the approval number, product specifications, and the impact on the company's business. The text is short (890 characters) and is an announcement of a regulatory approval event rather than a financial report or detailed filing. There is no financial data, no mention of annual or quarterly results, no management discussion, no voting results, or other report types. It is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2026-05-06 Chinese
第十一届董事会第七次会议决议公告
Regulatory Filings Classification · 75% confidence The document is a Chinese board resolution announcement (“第十一届董事会第七次会议决议公告”) detailing the board’s decision to convene an Extraordinary General Meeting to vote on a targeted A-share issuance plan and related matters. It is not reporting actual share issuance completion (so not SHA), nor detailing full financing results (so not CAP), nor is it a change in board composition (MANG), nor a notice of a shareholder meeting itself (PSI). It is a standard regulatory disclosure of board resolutions, fitting the general “miscellaneous regulatory announcement” category. Thus, it falls under Regulatory Filings (RNS).
2026-04-14 Chinese
关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is not an earnings release or financial report but a notice convening an extraordinary shareholders’ meeting with detailed agenda items, voting procedures, proxy authorization forms, and solicitation of votes. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-14 Chinese
国金证券股份有限公司关于人福医药集团股份公司2024年度募集资金存放与使用情况的专项核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's special verification opinion on the 2024 annual fundraising funds deposit and usage situation of Renfu Pharmaceutical Group Co., Ltd. It includes specifics about the amount raised, usage, balance, regulatory compliance, and audit opinions from an accounting firm. The content focuses on the management and use of raised funds, compliance with regulatory requirements, and audit verification, which aligns with a Capital/Financing Update. It is not a full annual report or audit report but a specialized verification related to fundraising and capital usage. Therefore, the document fits best under Capital/Financing Update (CAP). The document length and detail confirm it is a full report, not just an announcement or certification, so RPA or RNS are not appropriate.
2025-04-28 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.